VIVUS, Inc. is a biopharmaceutical company. The Company operates in the development and commercialization of therapeutic products segment. It provides over two therapies approved by the Food and Drug Association (FDA), which include Qsymia (phentermine and topiramate extended-release) for chronic weight management and STENDRA (avanafil) for erectile dysfunction (ED). The Company has completed the Phase II studies of Qsymia for the indication of Obstructive Sleep Apnea (OSA) and diabetes. Its Qsymia is available in over 40,000 certified retail pharmacies across the country. Its STENDRA is also approved by the European Commission (EC), under the name, SPEDRA, for the treatment of ED in the Europe. The United States Food and Drug Association approved a Supplemental New Drug Application (sNDA) for STENDRA. STENDRA is indicated to be taken approximately 15 minutes before sexual activity.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Biotechnology
- Sub-Industry: Pharmaceuticals
- Exchange: NASDAQ
- Symbol: VVUS
- CUSIP: 92855110
- Previous Close: $1.08
- 50 Day Moving Average: $1.15
- 200 Day Moving Average: $1.15
- 52-Week Range: $104,843,000.00 - $0.93
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -2.32
- P/E Growth: -15.00
- Market Cap: $114.28M
- Outstanding Shares: 104,843,000
- Beta: 1.29
- Net Margins: -78.63%
- Return on Assets: -16.44%
Companies Related to VIVUS:
- Debt-to-Equity Ratio: -6.03%
- Current Ratio: 2.71%
- Quick Ratio: 2.61%
What is VIVUS's stock symbol?
VIVUS trades on the NASDAQ under the ticker symbol "VVUS."
Where is VIVUS's stock going? Where will VIVUS's stock price be in 2017?
4 brokerages have issued 1 year price targets for VIVUS's shares. Their predictions range from $1.00 to $2.80. On average, they anticipate VIVUS's share price to reach $1.90 in the next year.
When will VIVUS announce their earnings?
VIVUS is scheduled to release their next quarterly earnings announcement on Tuesday, March, 7th 2017.
Who owns VIVUS stock?
VIVUS's stock is owned by many different of institutional and retail investors. Top institutional shareholders include Renaissance Technologies LLC (4.18%), Sarissa Capital Management LP (2.46%), Oxford Asset Management (0.32%), Menta Capital LLC (0.28%) and State Street Corp (0.10%). Company insiders that own VIVUS stock include John L Slebir, North Tide Capital, Llc and Santosh T Varghese.
Who sold VIVUS stock? Who is selling VIVUS stock?
VIVUS's stock was sold by a variety of institutional investors in the last quarter, including Menta Capital LLC. Company insiders that have sold VIVUS stock in the last year include North Tide Capital, Llc and Santosh T Varghese.
Who bought VIVUS stock? Who is buying VIVUS stock?
VIVUS's stock was purchased by a variety of institutional investors in the last quarter, including Sarissa Capital Management LP, Renaissance Technologies LLC, Oxford Asset Management and State Street Corp.
How do I buy VIVUS stock?
Shares of VIVUS can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of VIVUS stock cost?
One share of VIVUS stock can currently be purchased for approximately $1.09.